OTC Markets

OTC Pink® Basic Disclosure Guidelines

Disclosures for Fiscal Quarter ended September 30, 2016

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

NuVim, Inc.

2) Address of the issuer's principal executive offices

Company Headquarters
Address 1: 18327 Port Circle
Address 2: Lewes, Delaware 19958
Address 3:
Phone: 302.827.4052
Email: info@nuvim.com
Website(s): nuvim.com

IR Contact
Address 1: None
Address 2: _____
Address 3: _____
Phone: _____
Email: _____
Website(s): _____

3) Security Information

Trading Symbol: NUVM
Exact title and class of securities outstanding: Common Stock
CUSIP: 67071X100
Par or Stated Value: $0.00001 par value per share
Total shares authorized: 120,000,000 as of: September 30, 2016
Total shares outstanding: 90,286,436 as of: September 30, 2016

Additional class of securities (if necessary): N/A
Trading Symbol:
Exact title and class of securities outstanding:
CUSIP:
Par or Stated Value:
Total shares authorized: as of:
Total shares outstanding: as of:

Transfer Agent
Name: American Stock Transfer & Trust Co, LLC
Address 1: 6201 15th Avenue
Address 2: Brooklyn, NY 11219
Address 3:
Phone: 800.937.5449

Is the Transfer Agent registered under the Exchange Act?* Yes: ☒ No: ☐

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any restrictions on the transfer of security:

None

Describe any trading suspension orders issued by the SEC in the past 12 months.

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);

During the third and fourth quarters of 2015 NuVim issued a total of 1,900,000 shares in settlement of $ 314,017 of debt and unpaid interest and issued 500,000 shares for an interest rate reduction, extension of maturity, and release of conversion rights on $26,587 of debt.

B. Any jurisdictions where the offering was registered or qualified;

N/A

C. The number of shares offered;

N/A

D. The number of shares sold;

2,400,000

E. The price at which the shares were offered, and the amount actually paid to the issuer;

Debts aggregating $304,017 of principal and unpaid interest were cancelled and the terms of another debt of $26,587 were improved.

F. The trading status of the shares; and

Restricted

G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

Yes

5) Financial Statements

Provide the financial statements described below for the most recent fiscal year end or quarter end to maintain qualification for the OTC Pink Current Information tier. For the initial disclosure statement (qualifying for Current Information for the first time) please provide reports for the two previous fiscal years and any interim periods.

A. Balance sheet;
B. Statement of income;
C. Statement of cash flows;
D. Financial notes; and
E. Audit letter, if audited

The financial statements requested pursuant to this item shall be prepared in accordance with US GAAP by persons with sufficient financial skills.

You may either (i) attach/append the financial statements to this disclosure statement or (ii) post such financial statements through the OTC Disclosure & News Service as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial reports separately as described in part (ii) above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to otciq.com in the field below.

The following documents are hereby incorporated by reference:

The unaudited Quarterly Report for the Fiscal Quarter ended September 30, 2016 which was posted to otciq.com on November 14, 2016.

Information contained in a Financial Report is considered current until the due date for the subsequent Financial Report. To remain in the OTC Pink Current Information tier, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of its fiscal quarter-end date.

6) Describe the Issuer's Business, Products and Services

Describe the issuer's business so a potential investor can clearly understand the company. In answering this item, please include the following:

A. a description of the issuer's business operations;

NuVim, Inc., (the Company) founded in 1999 specializes in producing, marketing and distributing a dietary supplement under the NuVim brand that provides health conscious consumers with enhanced quality of life. Specifically, the NuVim products help strengthen the immune system, muscle and bone health and aid in consistent digestion while also delivering 100% of the daily requirement of vitamins C, E, B12 and zinc. The powder mix

form of the Company products are sold on line at www.nuvim.com and through Amazon on-line sales. The strawberry, vanilla and chocolate varieties of the powder mix products are packaged 30 individual servings to a box with the recommendation that the consumer use one serving per day. Consumers add the NuVim powder mix to yogurt, cereal, milk, juice drinks or bottled water. The ready to drink version of the products has been marketed in past years and the intent is to re-launch this form after the successful introduction of the new powder mix improved product line that is currently in development.

The new improved version of the product line is on schedule to be introduced next year. These new breakthrough products have been in development for over a year with internal resources, medical surgeons, dietary experts and product development professional consultants. NuVim considers the new products revolutionary. The products use an unique combination of compounds including antioxidants designed to help neutralize free radicals for maintaining healthy functioning body cells, assist in cardiovascular health, mental acuity, beneficial indigenous bacterial for the digestive system, ingredients for healthy skin and shorter recovery time when feeling fatigued and run down. All product ingredients are considered by the FDA as Generally Recognized As Safe (GRAS).

The NuVim improved all natural product line will **not** contain caffeine, fat, cholesterol, gluten, lactose or a high caloric level but will deliver a good source of fiber, a prebiotic, vitamins C, E, B12, D3, L-Citrulline and increased calcium absorption. It is an excellent product for professional and amateur athletes, the week-end warrior and everyday busy consumers who want to live a healthier more energetic quality of life.

In addition to the internal building business initiatives, NuVim continues to evaluate potential partners.

B. Date and State (or Jurisdiction) of Incorporation:

NuVim was incorporated in Delaware on September 16, 1999.

C. the issuer's primary and secondary SIC Codes;

5149

D. the issuer's fiscal year end date;

December 31

E. principal products or services, and their markets;

The NuVim dietary supplement products are marketed to both male and females in their later stages of life. The products may also help professional athletes, weekend warriors, and those incurring immune dysfunction or lack of energy and mental alertness.

7) Describe the Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

NuVim's headquarters is located in Lewes Delaware. No manufacturing facilities are owned by NuVim. The products are co-packed under the NuVim quality control supervision. No offices or distribution facilities are owned by NuVim. Sales are generated through broker networks on a commission basis, through direct sales, through e-commerce from Amazon and through prearranged contractual agreements.

8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Name	Title
Richard P. Kundrat	Chairman, CEO, & CFO
Calvin Hodock	Director
Stanley H. Moger	Director
Peter DeCrescenzo	Director
Doug Scott	Director
Dick Clark Productions, Inc.	Control Person (owns 7% of shares)

Excludes Depository Trust Company which is the nominal owner of 48.8% of the shares

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

   None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

   None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

   None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

   None

C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

Excludes Depository Trust Company which is the nominal owner of 48.8% of the shares

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel
Name: Mark A. Siegel
Firm: Siegel Law Offices
Address 1: 6627 Northwest 64th Street
Address 2: Boca Raton, FL 33496
Phone: 561.212.8035
Email: masiegel@gate.net

Accountant or Auditor
Name: Richard P. Kundrat
Firm:
Address 1: 18327 Port Circle
Address 2: Lewes, Delaware 19958
Phone: 302.827.4052
Email: rpkundrat@yahoo.com

Investor Relations Consultant
Name: None
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Other Advisor: Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement.
Name: None
Firm: _____
Address 1: _____

Address 2: _____
Phone: _____
Email: _____

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, Richard P. Kundrat certify that:

1. I have reviewed this Quarterly Disclosure Statement for the Fiscal Quarter ended September 30, 2016 of NuVim, Inc.;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

November 14, 2016

/s/ Richard P. Kundrat CEO

/s/ Richard P. Kundrat CFO

Chairman, CEO, & CFO